Plant Name: Abrus precatorius
Taxonomic Information:
Plant ID: NPO2865
Plant Latin Name: Abrus precatorius
Taxonomy Genus: Abrus
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
3816
Plant-of-the-World-Online:
469605-1
Used in Medicines:
Country/Region:
Brazil; Afghanistan; Pakistan; Tanzania; Indonesia; India; Laos; Malaysia; Rwanda; Jordan; Vietnam; Kenya; Thailand; Nigeria; China; PhilippinesTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCM; HomeopathyGeographical Distribution:
Brazil; Afghanistan; Bangladesh; Nepal; Costa Rica; Cambodia; Bahamas; Rwanda; Peru; Laos; Nigeria; Bolivia; Vanuatu; Thailand; Ecuador; Australia; Cuba; Papua New Guinea; Suriname; Guatemala; China; Jordan; Dominican Republic; Belize; United States; Tanzania; Netherlands; Pakistan; Philippines; Indonesia; New Caledonia; Mauritius; Trinidad and Tobago; Vietnam; French Guiana; Guyana; Haiti; Jamaica; Honduras; Myanmar; Nicaragua; India; Malaysia; Colombia; Sri Lanka; Kenya; Taiwan; Fiji
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| AURKB; AURKA; FLT3; KDR; | |
| CA4; CA12; CA7; | |
| ALDH1A1; NOX4; GFER; | |
| KDM4E; | |
| MMP12; MMP9; MMP2; MMP1; | |
| NFKB1; HIF1A; | |
| FUT7; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.992E-08 | 3.257E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 8.586E-08 | 6.232E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 6.694E-07 | 1.858E-03 | MMP1, MMP12, MMP2, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.997E-07 | 1.858E-03 | CA12, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 1.471E-06 | 2.288E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 7.119E-06 | 7.812E-03 | CYP1A1, HIF1A, LMNA, MMP2, NOX4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.727E-06 | 7.812E-03 | CA12, CA4, CA7 |
| MF | GO:0003824; catalytic activity | GO:0004222; metalloendopeptidase activity | 6.598E-06 | 7.812E-03 | MMP1, MMP12, MMP2, MMP9 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.483E-06 | 1.055E-04 | FLT3, MMP1, MMP2, HIF1A, MMP9, NFKB1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 6.720E-07 | 5.712E-05 | CA12, CA4, CA7 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.037E-05 | 2.937E-04 | MMP1, MMP2, MMP9 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 5.386E-05 | 1.145E-03 | MMP2, KDR, HIF1A, MMP9 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Cancer | C00-C96 | AURKA; KDR; NFKB1; FLT3; HIF1A; MMP9; MMP2; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Breast cancer | C50 | KDR; FLT3; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | AURKA; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | KDR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | KDR; FLT3; MMP9; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | AURKA; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AURKA; AURKB; KDR; FLT3; HIF1A; MMP9; MMP2; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKA; AURKB; FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; MMP2; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | KDR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
